Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels

Source of Review The Institute for Clinical and Economic Review developed an evidence report, including a systematic reviewof the literature, a costeffectiveness model, and a budget impact assessment, to support a public meeting of the New EnglandComparativeEffectiveness Public Advisory Council (CEPAC) on October 27, 2015.1 The report evaluates the comparative clinical effectiveness and comparative value of proprotein convertase subtilisin/ kexin type9 (PCSK9) inhibitors as a class for the treatmentof adults with familial hypercholesterolemiaor cardiovascular disease (CVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C) levels.